Molekulargenetische Diagnostik
Praxis Dr. Mato Nagel

Kombinierte familiäre Hyperlipämie mit Dysfunktion des Fettgewebes

Gliederung

Familiäre kombinierte Hyperlipämie
Kombinierte familiäre Hyperlipämie mit Dysfunktion des Fettgewebes
C5AR2
LEPR
LIPE
PNPLA2
PPARG
USF1
Kombinierte familiäre Hyperlipämie mit VLDL-Überproduktion
Kombinierte familiäre Hyperlipämie mit gestörtem VLDL-Metabolismus
Kombinierte familiäre Hyperlipämie mit gestörter LDL-Clearance

Referenzen:

1.

Balthasar N et. al. (2004) Leptin receptor signaling in POMC neurons is required for normal body weight homeostasis.

[^]
2.

Wisløff U et. al. (2005) Cardiovascular risk factors emerge after artificial selection for low aerobic capacity.

[^]
3.

Uchida T et al. (2005) Deletion of Cdkn1b ameliorates hyperglycemia by maintaining compensatory hyperinsulinemia in diabetic mice.

[^]
4.

Hansen SK et. al. (2005) Analysis of separate and combined effects of common variation in KCNJ11 and PPARG on risk of type 2 diabetes.

[^]
5.

et al. (2007) Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels.

[^]
6.

Scott LJ et al. (2007) A genome-wide association study of type 2 diabetes in Finns detects multiple susceptibility variants.

[^]
7.

Zeggini E et al. (2007) Replication of genome-wide association signals in UK samples reveals risk loci for type 2 diabetes.

[^]
8.

None (1978) Obese and diabetes: two mutant genes causing diabetes-obesity syndromes in mice.

[^]
9.

None (1973) Effects of parabiosis of obese with diabetes and normal mice.

[^]
10.

Tartaglia LA et. al. (1995) Identification and expression cloning of a leptin receptor, OB-R.

[^]
11.

Chua SC et. al. (1996) Phenotypes of mouse diabetes and rat fatty due to mutations in the OB (leptin) receptor.

[^]
12.

Chen H et. al. (1996) Evidence that the diabetes gene encodes the leptin receptor: identification of a mutation in the leptin receptor gene in db/db mice.

[^]
13.

Lee GH et. al. (1996) Abnormal splicing of the leptin receptor in diabetic mice.

[^]
14.

Considine RV et. al. (1996) The hypothalamic leptin receptor in humans: identification of incidental sequence polymorphisms and absence of the db/db mouse and fa/fa rat mutations.

[^]
15.

None (1996) Reflections on STAT3, STAT5, and STAT6 as fat STATs.

[^]
16.

Ghilardi N et. al. (1996) Defective STAT signaling by the leptin receptor in diabetic mice.

[^]
17.

Chung WK et. al. (1996) Mapping of the OB receptor to 1p in a region of nonconserved gene order from mouse and rat to human.

[^]
18.

Takaya K et. al. (1996) Molecular cloning of rat leptin receptor isoform complementary DNAs--identification of a missense mutation in Zucker fatty (fa/fa) rats.

[^]
19.

Vaisse C et. al. (1996) Leptin activation of Stat3 in the hypothalamus of wild-type and ob/ob mice but not db/db mice.

[^]
20.

Winick JD et. al. (1996) Identification of microsatellite markers linked to the human leptin receptor gene on chromosome 1.

[^]
21.

Takaya K et. al. (1996) Nonsense mutation of leptin receptor in the obese spontaneously hypertensive Koletsky rat.

[^]
22.

Chung WK et. al. (1996) Genomic structure of the human OB receptor and identification of two novel intronic microsatellites.

[^]
23.

Golden PL et. al. (1997) Human blood-brain barrier leptin receptor. Binding and endocytosis in isolated human brain microvessels.

[^]
24.

Gotoda T et. al. (1997) Leptin receptor gene variation and obesity: lack of association in a white British male population.

[^]
25.

Gloaguen I et. al. (1997) Ciliary neurotrophic factor corrects obesity and diabetes associated with leptin deficiency and resistance.

[^]
26.

Clément K et. al. (1998) A mutation in the human leptin receptor gene causes obesity and pituitary dysfunction.

[^]
27.

Sierra-Honigmann MR et. al. (1998) Biological action of leptin as an angiogenic factor.

[^]
28.

Ducy P et. al. (2000) Leptin inhibits bone formation through a hypothalamic relay: a central control of bone mass.

[^]
29.

Rosmond R et. al. (2000) Hypertension in obesity and the leptin receptor gene locus.

[^]
30.

Quinton ND et. al. (2001) A single nucleotide polymorphism (SNP) in the leptin receptor is associated with BMI, fat mass and leptin levels in postmenopausal Caucasian women.

[^]
31.

Wauters M et. al. (2001) Leptin receptor gene polymorphisms are associated with insulin in obese women with impaired glucose tolerance.

[^]
32.

Yiannakouris N et. al. (2001) The Q223R polymorphism of the leptin receptor gene is significantly associated with obesity and predicts a small percentage of body weight and body composition variability.

[^]
33.

Cohen P et. al. (2001) Selective deletion of leptin receptor in neurons leads to obesity.

[^]
34.

Tian Z et. al. (2002) Impaired natural killer (NK) cell activity in leptin receptor deficient mice: leptin as a critical regulator in NK cell development and activation.

[^]
35.

Bates SH et. al. (2003) STAT3 signalling is required for leptin regulation of energy balance but not reproduction.

[^]
36.

Kaneto H et. al. (2004) Possible novel therapy for diabetes with cell-permeable JNK-inhibitory peptide.

[^]
37.

Zhang EE et. al. (2004) Neuronal Shp2 tyrosine phosphatase controls energy balance and metabolism.

[^]
38.

Morton GJ et. al. (2005) Leptin action in the forebrain regulates the hindbrain response to satiety signals.

[^]
39.

de Luca C et. al. (2005) Complete rescue of obesity, diabetes, and infertility in db/db mice by neuron-specific LEPR-B transgenes.

[^]
40.

Park KS et. al. (2006) Polymorphisms in the leptin receptor (LEPR)--putative association with obesity and T2DM.

[^]
41.

Raju SV et. al. (2006) Activation of the cardiac ciliary neurotrophic factor receptor reverses left ventricular hypertrophy in leptin-deficient and leptin-resistant obesity.

[^]
42.

Farooqi IS et. al. (2007) Clinical and molecular genetic spectrum of congenital deficiency of the leptin receptor.

[^]
43.

Björnholm M et. al. (2007) Mice lacking inhibitory leptin receptor signals are lean with normal endocrine function.

[^]
44.

Richert L et. al. (2007) Bone mass in prepubertal boys is associated with a Gln223Arg amino acid substitution in the leptin receptor.

[^]
45.

Morioka T et. al. (2007) Disruption of leptin receptor expression in the pancreas directly affects beta cell growth and function in mice.

[^]
46.

Seo S et. al. (2009) Requirement of Bardet-Biedl syndrome proteins for leptin receptor signaling.

[^]
47.

Sun Q et. al. (2010) Genome-wide association study identifies polymorphisms in LEPR as determinants of plasma soluble leptin receptor levels.

[^]
48.

Duggal P et. al. (2011) A mutation in the leptin receptor is associated with Entamoeba histolytica infection in children.

[^]
49.

Czupryn A et. al. (2011) Transplanted hypothalamic neurons restore leptin signaling and ameliorate obesity in db/db mice.

[^]
50.

Ding L et. al. (2012) Endothelial and perivascular cells maintain haematopoietic stem cells.

[^]
51.

Marie CS et. al. (2012) Leptin protects host cells from Entamoeba histolytica cytotoxicity by a STAT3-dependent mechanism.

[^]
52.

Kunisaki Y et. al. (2013) Arteriolar niches maintain haematopoietic stem cell quiescence.

[^]
53.

Gupta RK et. al. (2010) Transcriptional control of preadipocyte determination by Zfp423.

[^]
54.

Zhang LJ et. al. (2015) Innate immunity. Dermal adipocytes protect against invasive Staphylococcus aureus skin infection.

[^]
55.

Sahin E et. al. (2011) Telomere dysfunction induces metabolic and mitochondrial compromise.

[^]
56.

Michalik L et. al. (2001) Impaired skin wound healing in peroxisome proliferator-activated receptor (PPAR)alpha and PPARbeta mutant mice.

[^]
57.

Tarrade A et. al. (2001) PPARgamma/RXRalpha heterodimers control human trophoblast invasion.

[^]
58.

Rocchi S et. al. (2001) A unique PPARgamma ligand with potent insulin-sensitizing yet weak adipogenic activity.

[^]
59.

Rosen ED et. al. (2002) C/EBPalpha induces adipogenesis through PPARgamma: a unified pathway.

[^]
60.

Ren D et. al. (2002) PPARgamma knockdown by engineered transcription factors: exogenous PPARgamma2 but not PPARgamma1 reactivates adipogenesis.

[^]
61.

Agarwal AK et al. (2002) A novel heterozygous mutation in peroxisome proliferator-activated receptor-gamma gene in a patient with familial partial lipodystrophy.

[^]
62.

Hara M et. al. (2002) Insulin resistance is attenuated in women with polycystic ovary syndrome with the Pro(12)Ala polymorphism in the PPARgamma gene.

[^]
63.

Harris SG et. al. (2002) Prostaglandin D(2), its metabolite 15-d-PGJ(2), and peroxisome proliferator activated receptor-gamma agonists induce apoptosis in transformed, but not normal, human T lineage cells.

[^]
64.

Yun Z et. al. (2002) Inhibition of PPAR gamma 2 gene expression by the HIF-1-regulated gene DEC1/Stra13: a mechanism for regulation of adipogenesis by hypoxia.

[^]
65.

Cui Y et. al. (2002) Loss of the peroxisome proliferation-activated receptor gamma (PPARgamma ) does not affect mammary development and propensity for tumor formation but leads to reduced fertility.

[^]
66.

Akiyama TE et. al. (2002) Conditional disruption of the peroxisome proliferator-activated receptor gamma gene in mice results in lowered expression of ABCA1, ABCG1, and apoE in macrophages and reduced cholesterol efflux.

[^]
67.

Ge K et. al. (2002) Transcription coactivator TRAP220 is required for PPAR gamma 2-stimulated adipogenesis.

[^]
68.

Pawliczak R et. al. (2002) 85-kDa cytosolic phospholipase A2 mediates peroxisome proliferator-activated receptor gamma activation in human lung epithelial cells.

[^]
69.

Ardlie KG et. al. (2002) Testing for population subdivision and association in four case-control studies.

[^]
70.

Fajas L et. al. (2002) E2Fs regulate adipocyte differentiation.

[^]
71.

Savage DB et al. (2002) Digenic inheritance of severe insulin resistance in a human pedigree.

[^]
72.

Marques AR et. al. (2002) Expression of PAX8-PPAR gamma 1 rearrangements in both follicular thyroid carcinomas and adenomas.

[^]
73.

Frederiksen L et. al. (2002) Comment: studies of the Pro12Ala polymorphism of the PPAR-gamma gene in the Danish MONICA cohort: homozygosity of the Ala allele confers a decreased risk of the insulin resistance syndrome.

[^]
74.

Sewter C et. al. (2002) Differential effects of adiposity on peroxisomal proliferator-activated receptor gamma1 and gamma2 messenger ribonucleic acid expression in human adipocytes.

[^]
75.

Girnun GD et. al. (2002) APC-dependent suppression of colon carcinogenesis by PPARgamma.

[^]
76.

Heaney AP et. al. (2002) Functional PPAR-gamma receptor is a novel therapeutic target for ACTH-secreting pituitary adenomas.

[^]
77.

Yu S et. al. (2003) Adipocyte-specific gene expression and adipogenic steatosis in the mouse liver due to peroxisome proliferator-activated receptor gamma1 (PPARgamma1) overexpression.

[^]
78.

Hegele RA et al. (2002) PPARG F388L, a transactivation-deficient mutant, in familial partial lipodystrophy.

[^]
79.

Fajas L et. al. (2002) The retinoblastoma-histone deacetylase 3 complex inhibits PPARgamma and adipocyte differentiation.

[^]
80.

Lohmueller KE et. al. (2003) Meta-analysis of genetic association studies supports a contribution of common variants to susceptibility to common disease.

[^]
81.

Savage DB et al. (2003) Human metabolic syndrome resulting from dominant-negative mutations in the nuclear receptor peroxisome proliferator-activated receptor-gamma.

[^]
82.

Kolehmainen M et. al. (2003) Effect of the Pro12Ala polymorphism in the peroxisome proliferator-activated receptor (PPAR) gamma2 gene on the expression of PPARgamma target genes in adipose tissue of massively obese subjects.

[^]
83.

Ameshima S et. al. (2003) Peroxisome proliferator-activated receptor gamma (PPARgamma) expression is decreased in pulmonary hypertension and affects endothelial cell growth.

[^]
84.

Nikiforova MN et. al. (2003) RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma.

[^]
85.

Welch JS et. al. (2003) PPARgamma and PPARdelta negatively regulate specific subsets of lipopolysaccharide and IFN-gamma target genes in macrophages.

[^]
86.

Qi C et. al. (2003) Transcriptional coactivator PRIP, the peroxisome proliferator-activated receptor gamma (PPARgamma)-interacting protein, is required for PPARgamma-mediated adipogenesis.

[^]
87.

Nakamichi Y et. al. (2003) PPAR-gamma overexpression suppresses glucose-induced proinsulin biosynthesis and insulin release synergistically with pioglitazone in MIN6 cells.

[^]
88.

Bruemmer D et. al. (2003) Regulation of the growth arrest and DNA damage-inducible gene 45 (GADD45) by peroxisome proliferator-activated receptor gamma in vascular smooth muscle cells.

[^]
89.

Wang C et. al. (2003) Cyclin D1 repression of peroxisome proliferator-activated receptor gamma expression and transactivation.

[^]
90.

Saez E et. al. (2003) Genetic deficiency in Pparg does not alter development of experimental prostate cancer.

[^]
91.

Dwight T et. al. (2003) Involvement of the PAX8/peroxisome proliferator-activated receptor gamma rearrangement in follicular thyroid tumors.

[^]
92.

Eriksson J et. al. (2003) The effects of the Pro12Ala polymorphism of the PPARgamma-2 gene on lipid metabolism interact with body size at birth.

[^]
93.

Memisoglu A et. al. (2003) Interaction between a peroxisome proliferator-activated receptor gamma gene polymorphism and dietary fat intake in relation to body mass.

[^]
94.

Rosen ED et. al. (2003) Targeted elimination of peroxisome proliferator-activated receptor gamma in beta cells leads to abnormalities in islet mass without compromising glucose homeostasis.

[^]
95.

Masud S et. al. (2003) Effect of the peroxisome proliferator activated receptor-gamma gene Pro12Ala variant on body mass index: a meta-analysis.

[^]
96.

Herzig S et. al. (2003) CREB controls hepatic lipid metabolism through nuclear hormone receptor PPAR-gamma.

[^]
97.

Song J et. al. (2003) Peroxisome proliferator-activated receptor gamma C161T polymorphisms and survival of Japanese patients with immunoglobulin A nephropathy.

[^]
98.

Hevener AL et. al. (2003) Muscle-specific Pparg deletion causes insulin resistance.

[^]
99.

He W et. al. (2003) Adipose-specific peroxisome proliferator-activated receptor gamma knockout causes insulin resistance in fat and liver but not in muscle.

[^]
100.

Orio F et. al. (2003) Exon 6 and 2 peroxisome proliferator-activated receptor-gamma polymorphisms in polycystic ovary syndrome.

[^]
101.

Kelly D et. al. (2004) Commensal anaerobic gut bacteria attenuate inflammation by regulating nuclear-cytoplasmic shuttling of PPAR-gamma and RelA.

[^]
102.

Evans RM et. al. (2004) PPARs and the complex journey to obesity.

[^]
103.

Akune T et. al. (2004) PPARgamma insufficiency enhances osteogenesis through osteoblast formation from bone marrow progenitors.

[^]
104.

Picard F et. al. (2004) Sirt1 promotes fat mobilization in white adipocytes by repressing PPAR-gamma.

[^]
105.

Patsouris D et. al. (2004) PPARalpha governs glycerol metabolism.

[^]
106.

Zhang J et. al. (2004) Selective disruption of PPARgamma 2 impairs the development of adipose tissue and insulin sensitivity.

[^]
107.

Hegele RA et. al. (2004) Unbuckling lipodystrophy from insulin resistance and hypertension.

[^]
108.

Tsai YS et. al. (2004) Hypertension and abnormal fat distribution but not insulin resistance in mice with P465L PPARgamma.

[^]
109.

Temelkova-Kurktschiev T et. al. (2004) Ala12Ala genotype of the peroxisome proliferator-activated receptor gamma2 protects against atherosclerosis.

[^]
110.

Buzzetti R et. al. (2004) The common PPAR-gamma2 Pro12Ala variant is associated with greater insulin sensitivity.

[^]
111.

Bulotta A et. al. (2005) The common -866G/A polymorphism in the promoter region of the UCP-2 gene is associated with reduced risk of type 2 diabetes in Caucasians from Italy.

[^]
112.

Kim KS et. al. (2004) Effects of peroxisome proliferator-activated receptor-gamma 2 Pro12Ala polymorphism on body fat distribution in female Korean subjects.

[^]
113.

Guan Y et. al. (2005) Thiazolidinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption.

[^]
114.

Pascual G et. al. (2005) A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-gamma.

[^]
115.

Uno K et. al. (2006) Neuronal pathway from the liver modulates energy expenditure and systemic insulin sensitivity.

[^]
116.

Hansen L et. al. (2006) The Pro12Ala variant of the PPARG gene is a risk factor for peroxisome proliferator-activated receptor-gamma/alpha agonist-induced edema in type 2 diabetic patients.

[^]
117.

Florez JC et. al. (2007) Effects of the type 2 diabetes-associated PPARG P12A polymorphism on progression to diabetes and response to troglitazone.

[^]
118.

Monajemi H et. al. (2007) Familial partial lipodystrophy phenotype resulting from a single-base mutation in deoxyribonucleic acid-binding domain of peroxisome proliferator-activated receptor-gamma.

[^]
119.

Lüdtke A et. al. (2007) Peroxisome proliferator-activated receptor-gamma C190S mutation causes partial lipodystrophy.

[^]
120.

Odegaard JI et. al. (2007) Macrophage-specific PPARgamma controls alternative activation and improves insulin resistance.

[^]
121.

Wan Y et. al. (2007) Maternal PPAR gamma protects nursing neonates by suppressing the production of inflammatory milk.

[^]
122.

Wan Y et. al. (2007) PPAR-gamma regulates osteoclastogenesis in mice.

[^]
123.

Are A et. al. (2008) Enterococcus faecalis from newborn babies regulate endogenous PPARgamma activity and IL-10 levels in colonic epithelial cells.

[^]
124.

Tang W et. al. (2008) White fat progenitor cells reside in the adipose vasculature.

[^]
125.

Chandra V et. al. (2008) Structure of the intact PPAR-gamma-RXR- nuclear receptor complex on DNA.

[^]
126.

Almeida PE et. al. (2009) Mycobacterium bovis bacillus Calmette-Guérin infection induces TLR2-dependent peroxisome proliferator-activated receptor gamma expression and activation: functions in inflammation, lipid metabolism, and pathogenesis.

[^]
127.

Choi JH et. al. (2010) Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPARgamma by Cdk5.

[^]
128.

Ryan KK et. al. (2011) A role for central nervous system PPAR-γ in the regulation of energy balance.

[^]
129.

Lu M et. al. (2011) Brain PPAR-γ promotes obesity and is required for the insulin-sensitizing effect of thiazolidinediones.

[^]
130.

Choi JH et. al. (2011) Antidiabetic actions of a non-agonist PPARγ ligand blocking Cdk5-mediated phosphorylation.

[^]
131.

Dutchak PA et. al. (2012) Fibroblast growth factor-21 regulates PPARγ activity and the antidiabetic actions of thiazolidinediones.

[^]
132.

Jonker JW et. al. (2012) A PPARγ-FGF1 axis is required for adaptive adipose remodelling and metabolic homeostasis.

[^]
133.

Cipolletta D et. al. (2012) PPAR-γ is a major driver of the accumulation and phenotype of adipose tissue Treg cells.

[^]
134.

Banks AS et. al. (2015) An ERK/Cdk5 axis controls the diabetogenic actions of PPARγ.

[^]